Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grapiprant + pembrolizumab in MSS CRC
NCT03658772Phase 1Completed
- Sponsor
- Arrys Therapeutics, Inc.
- Start
- Sep 2018
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of grapiprant in colorectal cancer (CRC), sponsored by Arrys Therapeutics, Inc. Primary endpoints: Safety and tolerability of grapiprant alone and in combination with pembrolizumab and Recommended Phase 2 Dose. Started Sep 2018; status: completed.
02
Drugs
grapiprant
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03658772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658772.